New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech
Galvani Bioelectronics, the new joint venture between Google’s health-care spinoff Verily and drug giant GSK, will develop a new generation of "bioelectronic medicines" – neuromodulating therapies to treat a wide range of chronic diseases. Brian Otis, CTO of Verily, tells Medtech Insight how the devices that will come out of Galvani differ from existing neuromodulation technologies.
You may also be interested in...
The value of revenue streams derived from new business models is increasingly defined by how well companies manage the data within their ecosystems. Managing the data in the "last mile" subset provides an opportunity for medtech companies to generate income in that revenue stream, says Maximilian Schmid, head of the Global MedTech Practice at Accenture Life Sciences.
As rheumatoid arthritis treatment improves in the biologics era, patients need fewer joint replacements. Instead, they now require more closely monitored, agile care, in the face of a growing shortage of qualified rheumatologists. These demands help propel digital health applications, bioelectronic devices and novel imaging modalities into the medtech spotlight.
While August may have broken the short summer bull run, last month's batch of venture fundraisings did have one redeeming feature – it recorded the biggest Series A round this year to date, a $50m deal by liquid biopsy company Karius.